Life (May 2022)

Genetic Association between TNFA Polymorphisms (rs1799964 and rs361525) and Susceptibility to Cancer in Systemic Sclerosis

  • Joanna Kosałka-Węgiel,
  • Sabina Lichołai,
  • Sylwia Dziedzina,
  • Mamert Milewski,
  • Piotr Kuszmiersz,
  • Anna Rams,
  • Jolanta Gąsior,
  • Aleksandra Matyja-Bednarczyk,
  • Helena Kwiatkowska,
  • Mariusz Korkosz,
  • Andżelika Siwiec,
  • Paweł Koźlik,
  • Agnieszka Padjas,
  • Wojciech Sydor,
  • Jerzy Dropiński,
  • Marek Sanak,
  • Jacek Musiał,
  • Stanisława Bazan-Socha

DOI
https://doi.org/10.3390/life12050698
Journal volume & issue
Vol. 12, no. 5
p. 698

Abstract

Read online

Tumor necrosis factor (TNF)-α is a proinflammatory cytokine that plays an important role in the pathogenesis of autoimmune diseases. The aim of the study was to establish an association between TNF-α promoter variability and systemic sclerosis (SSc). The study included 43 SSc patients and 74 controls. Four single nucleotide polymorphisms (rs361525, rs1800629, rs1799724, and rs1799964) located at the promoter of the TNFA gene were genotyped using commercially available TaqMan allelic discrimination assays with real-time PCR. The rs1799724 allele was associated with an increased SSc susceptibility (p = 0.028). In turn, none of the polymorphisms studied were related to the clinical and laboratory parameters of SSc patients, except for a higher prevalence of anti-Ro52 antibodies in the AG rs1800629 genotype in comparison to GG carriers (p = 0.04). Three of four cancer patients had both CT rs1799964 and AG rs361525 genotypes; thus, both of them were related to the increased risk of cancer, as compared to the TT (p = 0.03) and GG carriers (p = 0.0003), respectively. The TNFA C rs1799724 variant is associated with an increased risk of SSc, while the CT rs1799964 and AG rs361525 genotypes might enhance cancer susceptibility in SSc patients, although large observational and experimental studies are needed to verify the above hypothesis.

Keywords